Ibrutinib, Venetoclax Active in High - Risk, Seniors With CLL

Findings seen in phase 2 study of combo regimen for first - line treatment of chronic lymphocytic leukemia
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news